• Profile
Close

Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: A phase 2 randomized clinical trial

JAMA Aug 17, 2021

Rovers KP, Bakkers C, Nienhuijs SW, et al. - Results of this phase 2 trial support the feasibility as well as safety of administering perioperative systemic therapy in patients diagnosed with resectable colorectal peritoneal metastases (CPM); this justifies a phase 3 trial.

  • An open-label, parallel-group phase 2 randomized clinical trial was performed in 9 Dutch tertiary centers.

  • The analysis was performed including 79 patients randomized to perioperative systemic therapy (experimental arm) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone (control arm).

  • No significant difference was there between the trial arms regarding the proportions of macroscopic complete cytoreductive surgery (experimental arm, 89%; control arm, 86%) and major postoperative morbidity (experimental arm, 22%; control arm, 33%).

  • Per findings, perioperative systemic therapy appeared feasible, safe, and able to induce response of CPM

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay